MOESM1 of Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)
Hiroki Nakajima
Sadanori Okada
Takako Mohri
Eiichiro Kanda
Naoyuki Inaba
Yoko Hirasawa
Hiroaki Seino
Hisamoto Kuroda
Toru Hiyoshi
Tetsuji Niiya
Hitoshi Ishii
10.6084/m9.figshare.5938009.v1
https://springernature.figshare.com/articles/journal_contribution/MOESM1_of_Dapagliflozin_improves_treatment_satisfaction_in_overweight_patients_with_type_2_diabetes_mellitus_a_patient_reported_outcome_study_PRO_study_/5938009
Additional file 1. List of the 29 medical institutions participating in the study. The data on this file include the names of the 29 participating medical institutions in this multi-center study.
2018-03-01 05:00:00
Type 2 diabetes mellitus
Oral hypoglycemic agent
Sodium glucose cotransporters 2 inhibitors
SGLT2 inhibitors
Dapagliflozin
Treatment satisfaction
Oral Hypoglycemic Agent-Questionnaire
Body weight
Patient reported outcome
Quality of life